Mamiya Hiroaki, Wattanakamolkul Kittima, Li Nan, Wu David Bin-Chia, Hirozane Mariko, Igarashi Ataru
Department of Pharmaceutical Sciences, International University of Health and Welfare, Narita city, Chiba, Japan.
Value, Evidence and Access Department, Integrated Market Access, Johnson and Johnson, Tokyo, Japan.
Pharmacoecon Open. 2025 Jun 24. doi: 10.1007/s41669-025-00589-9.
BACKGROUND: Productivity is utilised inconsistently in value assessment and poses methodological and conceptual challenges for estimation. This systematic literature review aims to understand how productivity gain/loss for patients and caregivers was measured in health economic evaluation, identify the preferred instruments to capture productivity gain/loss and assess their properties. METHODS: A systematic literature review was conducted using PubMed, Ovid MEDLINE, Embase, Japan-specific (J-STAGE and Ichushi Web) and economic literature databases (Cost-Effectiveness Analysis (CEA) Registry, Paediatric Economic Database Evaluation (PEDE) and National Health Service Economic Evaluation Database (NHS EED)). Additional relevant data were identified using clinical trial registries and grey literature searches. Studies published between January 2021 and December 2023 which presented economic evaluations with outcomes relevant to productivity measures were included. Instruments were selected for practical relevance and frequent use in studies, while research-specific and single-study questionnaires were excluded. RESULTS: Among 1431 published health economic evaluations with productivity in the assessment, 152 were included in this review. These studies were almost equally distributed over the 3-year period, with a slightly higher number in 2023 versus 2021 [54 (35.5%) versus 48 (31.6%)]. In total, 118/152 studies reported patient measures only, 14/152 reported caregiver measures only and 20/152 reported both patient and caregiver measures. Based on the inclusion criteria, 20 of the 88 identified instruments were further investigated in this review. The Work Productivity and Activity Impairment Questionnaire (WPAI) [23 (15.1%)], Institute for Medical Technology Assessment (iMTA) Productivity Cost Questionnaire (iPCQ) [23 (15.1%)] and Trimbos/iMTA Questionnaire for Costs associated with Psychiatric Illness (TIC-P) [(8 (5.3%)] were the most commonly used instruments. All three instruments were reported as valid and reliable. All three instruments reported absenteeism, presenteeism and overall work impairment. WPAI additionally included information on daily activity impairment. The human capital approach (n = 18) and the friction cost approach (n = 17) were utilised to assign monetary value to the lost productivity. CONCLUSIONS: This review identified a significant number of health economic evaluations between 2021 and 2023, which included productivity loss in the assessment. Various instruments were used to measure productivity loss in these studies, while a few instruments were commonly used across studies. To ensure consistent measurement of productivity, it is crucial to establish a standard tailored to a country or region, considering differences across countries or regions. Furthermore, necessary adaptations should be made on the basis of the specific health intervention being studied. Last, maintaining transparency in all productivity evaluations is vital.
背景:在价值评估中,生产力的运用并不一致,这给估算带来了方法和概念上的挑战。本系统文献综述旨在了解在健康经济评估中如何衡量患者和照护者的生产力增减,确定用于衡量生产力增减的首选工具,并评估其特性。 方法:使用PubMed、Ovid MEDLINE、Embase、日本特有的数据库(J-STAGE和Ichushi Web)以及经济文献数据库(成本效益分析(CEA)注册库、儿科经济数据库评估(PEDE)和国家卫生服务经济评估数据库(NHS EED))进行系统文献综述。通过临床试验注册库和灰色文献检索确定了其他相关数据。纳入了2021年1月至2023年12月期间发表的、呈现与生产力衡量相关结果的经济评估研究。选择工具是基于其实际相关性和在研究中的频繁使用情况,同时排除特定研究和单研究问卷。 结果:在1431项已发表的包含生产力评估的健康经济评估中,本综述纳入了152项。这些研究在三年期间分布大致均匀,2023年的数量略多于2021年[54项(35.5%)对48项(31.6%)]。总共,152项研究中有118项仅报告了患者指标,14项仅报告了照护者指标,20项报告了患者和照护者指标。根据纳入标准,本综述对88种已识别工具中的20种进行了进一步研究。工作生产力与活动障碍问卷(WPAI)[23项(15.1%)]、医学技术评估研究所(iMTA)生产力成本问卷(iPCQ)[23项(15.1%)]和Trimbos/iMTA精神疾病相关成本问卷(TIC-P)[8项(5.3%)]是最常用的工具。所有这三种工具都被报告为有效且可靠。所有三种工具都报告了旷工、出勤主义和总体工作障碍。WPAI还包括了关于日常活动障碍的信息。人力资本法(n = 18)和摩擦成本法(n = 17)被用于为损失的生产力赋予货币价值。 结论:本综述发现2021年至2023年间有大量健康经济评估,其中评估中包含生产力损失。在这些研究中使用了各种工具来衡量生产力损失,同时有几种工具在各研究中普遍使用。为确保生产力的一致衡量,考虑到国家或地区间的差异,制定适合某个国家或地区的标准至关重要。此外,应根据所研究的具体健康干预措施进行必要的调整。最后,在所有生产力评估中保持透明度至关重要。
Health Technol Assess. 2001
Forum Health Econ Policy. 2024-6-1
Rev Port Cardiol (Engl Ed). 2021-2
Pharmacoeconomics. 2021-1
Am J Manag Care. 2020-8
Ann Rheum Dis. 2020-4-3